中国信达(01359)发布公告，于2025年9月26日，公司董事会2025年第七次会议通过三项决议，委任宋卫 刚先生为公司总裁，提名宋先生担任公司执行董事，以及提名王中泽先生担任公司独立非执行董事。 宋先生和王先生的董事任期自本公司股东大会审议通过且经国家金融监督管理总局核准其董事任职资格 之日起3年，任期届满均可以连选连任。 ...

康哲药业(00867)发布公告，旗下德镁医药有限公司(德镁医药，专业聚焦皮肤健康的创新型医药企业， 正申请于香港联合交易所有限公司主板独立上市)连同其附属公司取得磷酸芦可替尼乳膏(芦可替尼乳膏) 轻中度特应性皮炎(AD)的中国三期药物临床研究积极结果。 产品用于轻中度特应性皮炎的中国三期临床研究成功达到主要终点，即使用芦可替尼乳膏治疗8周，达 到研究者整体评估(IGA)评分为0或1分，且较基线改善≥2分的受试者比例，显著高于安慰剂 (63.0%vs9.2%，P<0.001)。关键次要终点，芦可替尼乳膏治疗8周达到湿疹面积及严重程度指数评分较 基线至少改善75%(EASI75)的受试者比例亦显著优于安慰剂(78.0%vs15.4%，P<0.001)。安全性方面，治 疗期出现的不良事件(TEAE)的严重程度大多数为轻度或中度，未发生导致研究药物用药终止的治疗期 出现的不良事件(TEAE)，整体安全耐受性良好。 此外，集团正积极推进产品在中国的新药上市申请(NDA)工作。 该试验是一项在中国人群开展的随机、双盲、安慰剂对照、多中心的临床研究，共入组192例患者，旨 在评估产品治疗轻中度AD的安全性和有效性。该研究组 ...

Group 1 - The company announced the resignation of Mr. Li Zhongcheng as the co-secretary, authorized representative, and legal document agent [1] - Mr. Wu Dongcheng has been appointed as the new co-secretary, authorized representative, and legal document agent, effective from September 26, 2025 [1] - Mr. Zhong Xueyin will continue to serve as another co-secretary [1]

根据计划及任何其他股份计划(包括但不限于现有购股权计划)将授予的所有奖励及购股权而可能发行的 股份数目上限合共不得超过采纳日期公司已发行股本的10%;而在该限额内，根据计划及任何其他股份 计划将授予服务供应商的所有奖励及购股权而可能发行的股份数目上限合共不得超过采纳日期已发行股 份总数的1%。 计划将使公司能够透过授予奖励的方式，向合资格参与者就其对集团作出的贡献或潜在贡献提供激励， 并使彼等的利益与集团的利益保持一致。除现有购股权计划外，公司授予奖励的能力为公司提供了另一 种更贴合每位合资格参与者需求的激励方式。 新火科技控股(01611)公布，董事会建议采纳一项符合上市规则第17章的股份奖励计划。 ...

Group 1 - The company Heng Rui Medicine (600276) announced a share buyback plan, investing 61.36 million RMB to repurchase 883,400 A-shares [1] - The buyback price per share ranges from 69.25 to 69.81 RMB [1]

与GnRH受体激动剂相比，GnRH受体拮抗剂无"点火效应"，可以快速竞争性结合GnRH受体并阻断其启 动，快速抑制FSH和LH的释放，进而抑制下游雌激素的分泌，缓解子宫肌瘤的进展，在较低的剂量下 可实现部分抑制，在更高的剂量下则达到完全抑制。此外，由于拮抗剂的作用可逆，在停药一段时间 后，当内源性GnRH重新结合受体时，患者的性腺功能有望恢复正常。CMS-D002作为一款口服非肽类 小分子GnRH受体拮抗剂，结合其优异的临床前表现，有望为患者提供更优的治疗选择。 CMS-D002将进一步丰富集团产品矩阵，为中国患者提供差异化用药选择，满足兼具良好疗效、安全性 与良好患者依从性药物的临床需求，使患者受益。CMS-D002将有效增强集团在妇科治疗领域的实力， 依托现有专家网络与市场资源，提升该领域的竞争力与市场地位。 集团正积极准备开展相关临床试验工作，力争该产品尽快上市。 康哲药业(00867)发布公告，集团自主研发的创新药CMS-D002胶囊(CMS-D002)于2025年9月25日获得中 国国家药品监督管理局(NMPA)签发的药物临床试验批准通知书，于9月26日收到药物临床试验批准通知 书。NMPA同意开展 ...

Summary of Key Points Core Viewpoint - The Hong Kong stock market experienced significant net inflows from northbound trading, with a total net buy of 10.541 billion HKD on September 26, 2023, indicating strong investor interest in specific stocks, particularly Alibaba, Horizon Robotics, and Tencent [1][5]. Group 1: Northbound Trading Activity - Northbound trading saw a net buy of 10.541 billion HKD, with 7.366 billion HKD from the Shanghai Stock Connect and 3.174 billion HKD from the Shenzhen Stock Connect [1]. - The most net bought stocks included Alibaba-W (09988), Horizon Robotics-W (09660), and Tencent (00700) [1][5]. Group 2: Individual Stock Performance - Alibaba-W (09988) had a net buy of 57.20 billion HKD, with a total trading volume of 110.62 billion HKD, resulting in a net inflow of 3.77 billion HKD [2]. - Horizon Robotics-W (09660) received a net buy of 8.63 billion HKD, with plans to use the proceeds from a share placement to expand its overseas market and support advanced driver-assistance solutions [5]. - Tencent (00700) attracted a net buy of 7.92 billion HKD, supported by its global digital ecosystem conference focusing on AI and internationalization [6]. - Xiaomi Group-W (01810) saw a net buy of 6.05 billion HKD, despite a stock price drop following a product launch event [6]. Group 3: Market Trends and Insights - The cumulative net buy for Alibaba in the month exceeded 68.5 billion HKD, reflecting strong confidence in its future capital expenditure plans and AI-related growth [5]. - Semiconductor stocks like SMIC (00981) and Hua Hong Semiconductor (01347) faced net sells of 1.45 billion HKD and 2.12 billion HKD, respectively, due to regulatory pressures from the U.S. government [7]. - The third-party AI-driven drug development service provider, Crystal Tech Holdings (02228), received a net buy of 1.9 billion HKD, indicating a growing interest in independent platforms in the biotech sector [7].

ST金鸿（000669）(000669.SZ)公告，公司收到子公司湖南神州界牌瓷业有限公司(简称"神州界牌")临时 停产的报告。为提升矿山开采的工艺技术水平，采用更为安全、环保与经济的开采工艺，神州界牌需临 时停产，对所属矿山开采系统进行全面的技术升级改造。复产时间将根据本次技术改造完成情况再行确 定。 ...

虽然中国环保行业的可持续发展仍将面临着前所未有的严峻挑战，公司将推动业务转型列为重中之重， 坚定地聚焦于"中国生物质燃气运营服务商"市场定位，力争在激烈的市场竞争实现长远发展。为进一步 提升集团的盈利能力及可持续发展，董事会正积极评估扩展现有业务及╱或投资新业务的机遇，以拓宽 集团的收入基础。 可能进行的收购事项一经落实将为一项具吸引力的投资机会，让集团参与中国信息科技业务，预期此举 将有助使集团的收益来源多元化，并提升股东回报。再者，公司留意到各行各业引入物联网(Io T)技术 及人工智能(AI)成为全球趋势，且营商步入数位化已成定局。因此，董事认为数位解决方案市场前景可 期，具有卓越的发展潜力。 智通财经APP讯，中国水业集团(01129)发布公告，于2025年9月26日，公司(作为买方)与卖方A(张志壠) 及卖方B(李雪颖)就公司为收购目标有限合伙(浙江自贸区善行企业管理咨询合伙企业(有限合伙))的全部 有限合伙权益而可能进行的收购事项A;及与卖方C(北京康运信息咨询中心(有限合伙))就公司为收购目标 公司(北京随身保典信息科技有限公司)的1%股权而可能进行的收购事项B订立两项不具法律约束力的谅 解备忘 ...

Core Insights - New World Development (00017) reported a solid performance for the fiscal year 2025, achieving a core operating profit of HKD 6 billion and setting a sales target of HKD 27 billion for fiscal year 2026 [1][2] Financial Performance - The company successfully completed bank refinancing of HKD 88.2 billion, extending the earliest loan maturity to June 30, 2028, which significantly improved liquidity [2] - Total debt and net debt both decreased during the reporting period, with capital expenditures (CAPEX) down 15% and operating expenditures (OPEX) down 16% year-on-year [2] - The average interest rate and total financing costs decreased due to interest rate cuts in the US and Hong Kong, contributing to a more favorable financial structure [2] Real Estate Business - The core real estate business performed strongly, achieving contract sales of HKD 26 billion, with HKD 11 billion from Hong Kong and RMB 14 billion from mainland China [3] - Notable projects included the "滶晨" project in Hong Kong, which became the top seller with over HKD 10.7 billion in sales, and the "广粤观邸" project in Guangzhou, which sold RMB 2 billion upon opening [3] Future Development Plans - The company has a robust land bank and plans to launch over 2,100 units in Hong Kong for fiscal year 2026, including projects in Kowloon City and West Kowloon [4] - Ongoing collaborations with partners like China Merchants Shekou and China Resources Land will yield additional residential units, enhancing the company's project pipeline [4] - New investment properties, including the second K11 in Guangzhou and upcoming projects in Shanghai and Hangzhou, are set to expand the company's portfolio [4]